Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2024-04-25 00:00:00 ET · period of report 2024-04-25 · accession 0000950170-24-048457 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-04-25 | 2024-04-25 | SYRE | Harwin Peter Evan | Dir | M - OptEx | $0.00 | +3.64M | 4.02M | +962% | $0 |
| DI | 2024-04-25 | 2024-04-25 | SYRE | Harwin Peter Evan | Dir | M - OptEx | $0.00 | -91.0K | 346.0K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-25 | M | A | 3,639,680 | $0.00 | 4,018,101 | I By Fairmount Healthcare Fund II L.P. | — | — | (F2) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 2 | Derivative | Series A Preferred Stock | 2024-04-25 | M | D | 90,992 | $0.00 | 346,045 | I By Fairmount Healthcare Fund II L.P. | — · — to — | 3,639,680 Common Stock | (F2) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. |